AntiTick Vaccine
Recombinant vaccines against tick-borne diseases that devastate East African livestock.
AntiTick develops recombinant vaccines protecting East African cattle and wildlife against tick-borne pathogens. Driven by reverse vaccinology and antigen discovery, it targets the diseases that hit cattle herds hardest and threaten regional food security — with in-vivo testing through CLARF and antigen production shared with RePROVaD.
Cattle
Primary Host
Recombinant
Subunit approach
Research
Current stage
Why tick-borne disease
Ticks and the pathogens they carry are among the costliest constraints on African livestock production.
Our approach
- Reverse vaccinology and pan-genome analysis to find conserved, protective antigens
- Recombinant subunit antigens expressed and purified in-house
- Immunogenicity and challenge studies in livestock models at CLARF
- A path toward an affordable, locally produced anti-tick vaccine.
The challenge
- Tick-borne diseases cause major cattle mortality and lost productivity across East Africa
- Acaricide reliance drives resistance, residue and recurring cost for farmers
- Conventional vaccines are limited, imported and expensive
One health, one continent. Protecting livestock protects livelihoods, food security, and export markets—and reduces the disease burden shared between animals and people.
